Recommendation of the President – Imfinzi (durvalumab)
On 16 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 147/2025 on the reimbursement of the drug Imfinzi (durvalumab) under drug program B.6 “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”